Boston Scientific: Small Devices, Big Expectations | EP025

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Boston Scientific: Small Devices, Big Expectations | EP025

Listen for free

View show details

Boston Scientific: Small Devices, Big Expectations | EP025AI Investment Edge: Stocks, Markets & Money · Research checked 19 October 2026.A device only a few centimetres across can change a cardiac procedure. The investment question is harder: can innovation, reliable delivery and cash generation meet the expectations in Boston Scientific’s share price?Explore the dated Boston Scientific research, financial reviews and complete forecasts at iPulse AI.Dated model view: The released September research assigned Strong Buy at both its one-year and five-year horizons, with fixed endpoints 18 September 2027 and 18 September 2031. These are ORIGINAL non-adjusted model labels on the September18 reference of US$43.34; they have not been newly rescored at the current price. Current-reference scenario returns below are calculated separately. The positive view depends on competitive execution, recovery and cash after financing.What Boston Scientific sellsBoston Scientific makes medical devices used by hospitals, clinics and doctors in heart-rhythm, digestive, urological, vascular and chronic-pain procedures. Much of its revenue comes from devices used in procedures, alongside implants and supporting equipment. Cardiovascular contributed about two-thirds of Q2 sales; MedSurg supplied the rest.FARAPULSE uses catheter-delivered pulsed electric fields to treat selected atrial-fibrillation patients. WATCHMAN is a different implant: it closes a small pocket in the heart to reduce stroke risk in suitable patients. It does not treat the electrical rhythm itself. Clinical usefulness, regulatory labels, hospital purchasing and insurer payment are separate tests.Four financial tests, after the cyber disruptionThe latest reported quarter is Q2 ended 30 June 2026, released 29 July. Q3 results remain ahead. The August 25 cyber incident occurred after Q2 and cannot explain June-quarter results.* Earnings and cash: Q2 sales were US$5.442bn, up 7.5% reported and 7.0% organically. GAAP EPS was US$0.61; adjusted EPS US$0.86. H1 common net income of US$2.247bn included a US$384m discrete tax benefit. H1 operating cash flow was US$1.822bn versus US$1.827bn a year earlier. Adjusted EPS, reported profit and cash are different measures.* Margins: Q2 GAAP operating margin was 21.6%, versus 28.4% adjusted. The GAAP gross-margin bridge included an US$83m tariff recovery that the company removed from its adjusted measure. Mix, competition and costs determine how much growth reaches profit.* Balance sheet: June 30 unrestricted cash was US$539m against US$12.624bn carrying debt, or about US$12.085bn debt less that cash. These amounts precede any completed Penumbra acquisition. The pending deal’s approximately US$11bn cash portion is intended to be financed with cash and new debt; it is not all already borrowed. The announced enterprise value was about US$14.5bn.* Investment: H1 PP&E and internal-software purchases were US$372m, while expensed R&D was US$1.069bn. Acquisitions and strategic investments are additional uses of cash. US$1.822bn operating cash minus US$0.372bn purchases gives a derived H1 US$1.450bn remainder. This narrow subtraction is not the company’s non-GAAP free-cash-flow measure, which also includes disposal proceeds. Low physical capex does not mean low total investment.MiRus involved an additional US$1.5bn investment for a 33.75% nonvoting stake and an option, not ownership of the whole TAVR business; SIEGEL is investigational. Restructuring expects US$700–800m charges through 2029, including US$600–700m future cash costs. Intended gross annual benefits of about US$500m are partly to be reinvested.Current outlook: On September 8 Boston said it was unlikely to meet the July Q3/full-year sales-growth and adjusted-EPS ranges after manufacturing, order and shipping disruption. It supplied no replacement numerical ranges. September 9 restoration of operations does not establish recovered revenue or reinstate July guidance. September 22 investigation findings reported no evidence of ongoing activity after containment within the stated scope; they were not a universal guarantee about every system or a financial recovery forecast. A fresh normalized earnings multiple is not established here.US$44.24 and the fixed-date scenariosExact instrument: Boston Scientific ordinary common stock, BSX.NYSE / USD. The recording-reference Alpaca IEX trade checked October 19 was US$44.24, dated 19 October at 10:34:33 New York /18:34:33 Dubai (14:34:33.625UTC). This is a dated regular-session IEX observation, not a certified consolidated market close. A finalization refresh returned US$44.445 at 11:04:20 New York /19:04:20 Dubai (15:04:20.164UTC). The recording and its complete scenario calculations retain the explicitly dated US$44.24 reference; the later tick is not a new research rescore.The September research retains endpoint dates 18 September 2027 and 18 September 2031, approximately 11 months and 4 years 11 months from this ...

No reviews yet